An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention

Trial Profile

An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Apixaban (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Stroke
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 28 Mar 2017 Planned End Date changed from 1 Dec 2018 to 28 Dec 2018.
    • 28 Mar 2017 Planned primary completion date changed from 1 Dec 2018 to 27 Dec 2018.
    • 11 Jul 2016 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top